



Following a Moving Target: Current and Emerging Strategies for the Prevention and Management of COVID-19 in Patients with Multiple Sclerosis

As our understanding of COVID-19 advances, so too does our understanding of its impact on multiple sclerosis (MS). Drs. Scott Newsome, Avindra Nath, and Gavin Giovannoni will help learners navigate the complexities of patient-specific factors (e.g., disability status, MS subtypes) and disease-modifying therapies (DMTs) to help improve both MS and COVID-related outcomes. Through in-depth discussion, the faculty will provide invaluable guidance on the optimal timing of DMT therapy post-vaccination while also equipping participants with practical strategies for prophylactic and outpatient COVID management in MS patients. This program explores real-world outcomes and emerging clinical trial data, enabling participants to assess the evolving landscape of COVID-19 care in the context of MS.

This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC and was developed in partnership with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).

This activity is supported by an educational grant from AstraZeneca.

To view the activity and obtain 1.0 *AMA PRA Category 1 Credit*[™] Please click here: https://bit.ly/MS_COVIDactrims